ST. HELIER, Jersey--(BUSINESS WIRE)--
Novocure (NASDAQ: NVCR) today announced 43 presentations on Tumor Treating Fields will be featured at the Society for Neuro-Oncology 2020 Virtual Annual Meeting on November 19 through November 21. The presentations include two oral presentations and cover a broad and growing range of topics, with 36 of the 43 presentations prepared by external authors.
The oral presentations on Tumor Treating Fields include:
- Data from EF-19, a post-approval registry study of Tumor Treating Fields in recurrent glioblastoma (GBM), supporting results from Novocure’s EF-11 phase 3 pivotal trial in recurrent GBM and confirming the effectiveness and safety of Tumor Treating Fields as a monotherapy.
- Therapeutic implications of conditional vulnerabilities caused by Tumor Treating Fields exposure in novel combination therapies for non-small cell lung cancer (NSCLC) and brain metastases from NSCLC. Study results suggest that the combination of cisplatin and etoposide together with Tumor Treating Fields may be beneficial for NSCLC patients and patients with brain metastases from NSCLC.
Highlighted topics among poster presentations include the TRIDENT study evaluating Tumor Treating Fields in combination with radiation therapy and temozolomide, long-term survival in GBM patients after Tumor Treating Fields therapy, Tumor Treating Fields in combination with immunotherapy, a subgroup analysis of the EF-14 trial focusing on efficacy of Tumor Treating Fields in elderly patients, optimizing use of Tumor Treating Fields during Covid-19, and safety and quality of life of GBM patients treated with Tumor Treating Fields in China.
“From our first presentation at the SNO Annual Meeting in 2008 to today, we and our external partners have shared nearly 300 presentations on Tumor Treating Fields, strengthening our foundational understanding of our therapy and our science every year,” said Dr. Ely Benaim, Novocure’s Chief Medical Officer. “It remains an honor for us to participate and engage with our scientific colleagues at one of the most important neuro-oncology conferences worldwide. We look forward to gathering virtually to share our work and learn from our partners.”
Oral Presentations
(Abstract #: CBIO-01) Therapeutic implications of conditional vulnerabilities caused by Tumor Treating Fields exposure in novel combination therapies for non-small cell lung cancer and brain metastases from non-small cell lung cancer. N, Karanam, M. Story. (Experimental and Translation Sciences Session I)
(Abstract #: CTNI-77) EF-19: a post-approval registry study of Tumor Treating Fields (TTFields) in recurrent glioblastoma (rGBM). J. Zhu, R. O’Donnell, S. Goldlust, Z. Ram. (Clinical Trials Session I)
Poster Presentations
(Abstract #: CTIM-17) Phase I study of the safety and immunogenicity of personalized neoantigen vaccines and Tumor Treating Fields in patients with newly diagnosed glioblastoma. J. Kodysh, A. Rubinsteyn, A. Blazquez, J. Mandeli, N. Bhardwaj, A. Hormigo. (Clinical trials: Immunologic)
(Abstract #: NIMG-37) Delayed pseudoprogression in two patients undergoing TTFields treatment for newly diagnosed glioblastoma. A. Lowman, S. Hurrell, S. Bobholz, J. Connelly, E. Cochran, W. Mueller, S. McGarry, M. Brehler, P. LaViolette. (Neuro-imaging)
(Abstract #: INNV-10) Effects of TTFields Usage and Duration of Usage on Cellularity and Ki67 Distributions at Autopsy. S. Bobholz, A. Lowman, J. Connelly, E. Cochran, W. Mueller, S. McGarry, M. Brehler, P. LaViolette. (Innovations in patient care)
(Abstract # NCOG-26) Impact of Gender on Tumor Treating Fields Compliance in Patients with Glioblastoma. L. Karpf, S. Chawla, L. Desiderio, S. Mohan. (Outcome measures and neuro-cognitive outcomes)
(Abstract #: CTNI-21) Scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma. R. Miller, A. Song, A. Ali, V. Bar-Ad, N. Martinez, J. Glass, D. Andrews, K. Judy, J. Evans, C. Farrell, M. Werner-Wasik, I. Chervoneva, M. Ly, J. Palmer, H. Liu, W. Shi. (Clinical trials: Non-immunologic)
(Abstract #: CTIM-04) Updates for a phase 2 open-labeled study of pembrolizumab plus TTFields plus maintenance temozolomide in patients with newly diagnosed glioblastoma (2-THE-TOP). A. Ghiaseddin, S. Warren, A. Allen, D. Sampson, D. Chen, A. Sherman, V. Greene, M. Rahman, D. Tran. (Clinical trials: Immunologic)
(Abstract #: NCOG-52) Tumor Treating Fields in Meningioma. C. Mawrin. (Outcome measures and neuro-cognitive outcomes)
(Abstract #: CTNI-59) First safety analysis of anaplastic meningioma patients treated with Tumor Treating Fields (TTFields). C Mawrin. (Clinical trials: Non-immunologic)
(Abstract #: CTNI-71) TTFields in routine clinical care of newly diagnosed GBM patients in Germany – first report on the fully enrolled TIGER study population. O. Bähr, G. Tabatabai, R. Fietkau, R. Goldbrunner, M. Glas. (Clinical trials: Non-immunologic)
(Abstract #: CTNI-46) A Phase II Trial of Tumor Treating Fields (TTFields) Concomitant with Radiosurgery for the Treatment of Recurrent, Bevacizumab-naïve Glioblastoma. M. Harat, M. Blok, M. Adamczak-Sobczak, P. Szymanski, I. Miechowicz, B. Malkowski. (Clinical trials: Non-immunologic)
(Abstract #: CTNI-79) PriCoTTF Trial: A phase I/II trial of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma. S. Kebir, L. Lazaridis, T. Schmidt, C. Oster, D. Pierscianek, N. Guberina, C. Kleinschnitz, M. Proescholdt, P. Hau, A. Grosu, U. Sure, B. Scheffler, M. Stuschke, M. Glas. (Clinical trials: Non-immunologic)
(Abstract #: RTID-06) Enhancing Tumor Treating Fields therapy for recurrent glioblastoma with targeted and individualized skull remodeling surgery. A multi-center randomized phase 2 trial. N. Mikic, A. Korshoej. (Randomized Trials in Development)
(Abstract #: RTID-12) Phase 2 trial of Tumor Treating Fields (TTFields) plus radiation therapy (RT) plus temozolomide (TMZ) compared to RT plus temozolomide in newly diagnosed glioblastoma (ndGBM). R. Grossman, D. Limon, F. Bokstein, C. Harosh, D. Blumenthal, Z. Ram. (Randomized Trials in Development)
(Abstract #: NIMG-58) The effect of cell confluence on the distribution of Tumor Treating Fields. T. Marciano, S. Levi, Z. Bomzon. (Neuro-imaging)
(Abstract #: NIMG-65) Study of local perturbation in computational modelling on Tumor Treating Fields (TTFields) therapy. O. Zeevi, Z. Bomzon, T. Marciano. (Neuro-imaging)
(Abstract #: INNV-05) Tumor Treating Fields (TTFields) treatment planning for a patient with astrocytoma in the spinal cord. J. De Los Santos, S. Arvatz, O. Zeevi, S. Levi, Z. Bomzon, T. Marciano. (Innovations in patient care)
(Abstract #: CBIO-09) Intratumoral heterogeneity of dielectric properties in glioblastoma. M. Proescholdt, A. Haj, C. Doenitz, N. Schmidt, Z. Bomzon. (Cell biology (cell cycle regulation, DNA repair/modulation))
(Abstract #: RBIO-04) New Therapeutic Delivery Methods for Tumor-Treating Fields for Higher Efficacy. K. Carlson, Z. Bomzon, J. Arle. (Radiobiology)
(Abstract #: COVD-17) Tumor Treating Fields for glioblastoma therapy during the COVID-19 pandemic: Expert consensus on use and experience. N. Gatson, J. Barnholtz-Sloan, J. Drappatz, R. Henriksson, A. Hottinger, P. Hinoul, C. Kruchko, V. Puduvalli, D. Tran, E. Wong, M. Glas. (Innovations in patient care)
(Abstract #: COVD-04) Real-world perspectives: Tumor Treating Fields (TTFields) utility to optimize treatment of patients with glioblastoma (GBM) amidst COVID-19 pandemic. P. Frongillo, M. Shackelford, L. Rain. (Innovations in patient care)
(Abstract #: NCOG-36) First health utilities of glioblastoma patients using TTFields treatment. G. Chavez, C. Proescholdt. (Outcome measures and neuro-cognitive outcomes)
(Abstract #: EXTH-76) The inovivo system: a novel preclinical tool for in vivo delivery of Tumor Treating Fields (TTFields). S. Davidi, R. Blat, A. Shteingauz, Y. Porat, M. Giladi, U. Weinberg, Y. Palti. (Preclinical Experimental Therapeutics)
(Abstract #: EXTH-69) Increased cancer cell permeability following Tumor Treating Fields (TTFields) application in vitro. T. Voloshin, Y. Porat, N. Kaynan, A. Klein-Goldberg, R. Paz, A. Volodin, M. Giladi, U. Weinberg, Y. Palti. (Preclinical Experimental Therapeutics)
(Abstract #: TAMI-04) Tumor Treating Fields (TTFields) hinder glioma cell motility through regulation of microtubule and actin dynamics. T. Voloshin, R. Schneiderman, A. Volodin, R. Shamir, N. Kaynan, E. Zeevi, L. Koren, A. Klein-Goldberg, R. Paz, M. Giladi, Z. Bomzon, U. Weinberg, Y. Palti. (Tumor Microenvironment/Angiogenesis/Metabolism/Invasion)
(Abstract #: EXTH-31) Increasing Tumor Treating Fields (TTFields) efficacy by targeting the G2 cell cycle checkpoint with combined Wee1 or Chk1 inhibitors in glioblastoma cell lines. P. Slangen, M. de Gooijer, M. van Geldorp, O. van Tellingen, G. Borst. (Preclinical Experimental Therapeutics)
(Abstract #: EXTH-33) Valproic acid enhances anti-proliferative effects of Tumor Treating Fields on patient-derived gliosarcoma cells in vitro. S. Michelhaugh, S. Mittal. (Preclinical Experimental Therapeutics)
About Novocure
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields to disrupt cancer cell division. Novocure’s commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit or follow us at .
Forward-Looking Statements
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 27, 2020 and its Quarterly Report on Form 10-Q filed on April 30, 2020, as amended to date, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.
View source version on businesswire.com:
